Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T4314 |
EPZ020411
EPZ020411 2HCl |
Histone Methyltransferase | Chromatin/Epigenetic |
EPZ020411是一种特异性有效的 PRMT6 抑制剂, IC50 为 10 nM,比作用于 PRMT1 和 PRMT8 的选择性高10倍多。 | |||
T22325 |
EPZ020411 hydrochloride
EPZ020411 HCl |
Histone Methyltransferase | Chromatin/Epigenetic |
EPZ020411 hydrochloride 是一种选择性的和有效的 PRMT6抑制剂,IC50=10 nM。 | |||
T4334 |
EPZ020411 2HCl (1700663-41-7(free base))
|
Histone Methyltransferase | Chromatin/Epigenetic |
EPZ020411 2HCl (1700663-41-7(free base)) 是一种有效且特异性的小分子 PRMT6 抑制剂 (IC50=10 nM)。 | |||
T69922 | EPZ020411 HCl | ||
EPZ020411 is a potent and selective PRMT6 inhibitor tool compound. EPZ020411 shows good bioavailability following subcutaneous dosing in rats making it a suitable tool for in vivo studies. EPZ020411 suppresses RCC1 arginine methylation and improves the cytotoxic activity of radiotherapy against GSC brain tumor xenografts. | |||
T71899 |
Verubecestat TFA
|
||
Verubecestat, also known as MK-8931 or SCH 900931, is a potent and selective beta-secretase inhibitor, and BACE1 protein inhibitor or Beta-site APP-cleaving enzyme 1 inhibitor. Verubecestat is a promising novel therapeutic drug candidate in Alzheimer's disease. Verubecestat reduced Aβ cerebral spinal fluids (CSF) levels up to 92% and was well tolerated by patients. |